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The assessment of the general inflammatory condi­
tion of patients with autoimmune connective tissue 
disorders (ACTD) is a major challenge. The use of tra­
ditional inflammatory markers including CRP-levels 
and erythrocyte sedimentation rate (ESR) is limited by 
several preanalytical factors and their low specifici­
ties. Soluble urokinase plasminogen activator recep­
tor (suPAR) is one of the novel candidate markers that 
is increasingly used in immune mediated disorders. 
In our studies we compared suPAR levels of patients 
with rheumatoid arthritis (RA), systemic lupus erythe­
matosus (SLE), systemic sclerosis (SSc) and ankylosing 
spondylitis with those of healthy controls.
suPAR provided valuable clinical information on dis­
ease activity in RA, SLE and SSc. We identified a sub­
group of remitted RA patients, who presented still 
clinical symptoms of inflammatory activity which cor­
related to high plasma suPAR (while ESR and CRP were 
normal). In SLE we established specific suPAR cut-off 
values that support the discrimination between pa­
tients with high and those with moderate SLE activ­
ity. In patients with SSc suPAR correlated with objec­
tive measures of lung and other complications.
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In the majority of ACTDs including SLE, SSc or RA, 
suPAR is seemingly a good biomarker that would 
provide valuable clinical information. However, 
before the introduction of this novel parameter 
in laboratory repertoire important issues should 
be elucidated. These include the establishment 
of appropriate and disease specific cutoff val­
ues, clarification of interfering preanalytical val­
ues and underlying conditions and declaration 
of age- and gender-specific reference ranges.
«£♦ «£♦
INTRODUCTION
Inflammation is a characteristic hallmark of 
relapsed autoimmune connective tissue disor­
ders (ACTD). The treating physician's challenge 
is to determine the extension of inflammation 
and to decide whether the patient requires an 
intervention or therapy should be modified. 
Inflammatory markers, therefore, are generally 
used to assess ACTD patients' general condi­
tion. CRP-levels and erythrocyte sedimentation 
rate are among the most frequently ordered 
lab tests. However, the information provided by 
these tests is limited by their low sensitivity and 
the number of interfering preanalytical factors 
such as diurnal cycle, way of sampling or even 
physical exercise. Therefore, novel biomarkers 
that indicate the presence of severe inflamma­
tion in ACTD are highly warranted. suPAR is one 
of the promising candidates that we investigat­
ed extensively in patients with different ACTDs.
Urokinase-type plasminogen activator recep­
tor (uPAR) is expressed on various cell types, 
including immune, smooth muscle and endo­
thelial cells (1,2). When this receptor dissoci­
ates from the cell surface, suPAR, the soluble 
form of uPAR is created. suPAR is detectable 
with standard ELISA tests in low concentrations 
in non-diseased people. Its benefits over tradi­
tional acute phase proteins are that its levels
do not depend on diurnal variation and fasting 
state (3). suPAR is readily resistant to preana­
lytical conditions such as freezing and thawing 
(4). Due to its stability it may be a candidate 
as an assessable biomarker for inflammation. 
According to the data available, inflammatory 
response leads to elevated plasma suPAR levels 
in many inflammatory diseases (5) which is pre­
dictive to a worse prognosis. The clinical value of 
suPAR was investigated most extensively in sys­
temic inflammatory response syndrome (SIRS) 
and in patients with septic conditions. Current 
evidence unanimously indicates that levels of 
suPAR are increased in SIRS and may be used 
for risk stratification of patients with SIRS (6,7). 
Findings indicate that suPAR predicts better ad­
verse outcome following sepsis than traditional 
markers including CRP levels (8,9,10).
During the last five years our team made an 
extensive work to assess the clinical utility of 
suPAR levels in ACTD. In our studies we com­
pared plasma suPAR levels of different and well- 
characterized patient ACTD subgroups such as 
those with rheumatoid arthritis (RA) (11), sys­
temic lupus (SLE) (12), systemic sclerosis (SSc) 
(13), and ankylosing spondylitis (AS) (14) with 
29 healthy control subjects. Healthy controls 
had a negative history of rheumatic symptoms 
and negative status upon detailed physical and 
laboratory examination. Written informed con­
sent was obtained from all participants, and our 
study was reviewed and approved by the Ethics 
Committee of the institution. The studies were 
adhered to the tenets of the most recent revi­
sion of the Declaration of Helsinki.
For the purpose of suPAR determination we 
collected EDTA anticoagulated fasting blood 
samples from patients and controls, separat­
ed plasma and stored at -80°C until measure­
ment. Plasma suPAR concentrations were mea­
sured with the suPARnostic Flex ELISA assay 
(ViroGates A/S, Birkerod, Denmark) and were 
related to ESR, CRP and clinical status.
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T a b le  Su m m a ry  o f su P A R , C -re a ctiv e  protein (C R P ) and  eryth ro cyte
sedim entation  rate (E S R )  va lu e s  in autoim m une co n n e ctive  t issu e  
d iso rd e rs  (A C T D ) in c lu d in g  rheum atoid  arh tritis  (R A ), an ky lo sin g  
sp o n d ylit is  (A S ), sy ste m ic  lu p us (S L E )  and sy ste m ic  s c le ro s is  (S S c )
Dem ographic
ch a ra cte ristics Healthy controls 
n = 29
RA A S S L E S S c
and inflam m atory 
m arkers
(n=120) (n=33) (n= 89) (n = 83)
Age, years 55 61 41* 44 51.5[46-69] (48 -  72) [35-45] [34-59] [44-60]
Gender, male/female 10/19 46/74 24/9 10/79 16/67
suPAR, ng/mL 2.80[2.06-3.42]
4.24
(3 .19 -5 .4 0)
2.97
[2.57-3.80]
4.58*
[3.72-6.30]
4.02*
[3.19-5.53]
CRP, mg/L 2.70 4.00 10.00* 3.90 3.50[BLD-4.15] (BLD -  9.83) [2.75-25.80] [BLD-9.55] [1.80-8.40]
ESR, mm/h 10 21 17* 28* 18*[7-14] (1 2 -3 6 ) [10-33] [17-50] [8-28]
BLD=below the level of detection; * p<0.05 compared to the control
Based on data published in refs 11-14.
suPAR IN RHEUMATOID ARTHRITIS (11)
Rheumatoid arthritis (RA) is a chronic inflam­
matory disease leading to the erosion of the 
cartilage and bone, and invasive growth of sy­
novial pannus tissue. The Disease Activity Score 
(DAS28) reflecting the severity of RA is based 
on clinical signs and symptoms along with CRP 
and ESR (15). RA is regarded as active above a 
DAS28 score of 2.6, however, patients in remis­
sion (DAS28 score <2.6) might also be affected 
by inflammatory activity.
In our RA study we enrolled 120 RA patients at 
various stages of disease duration and activity 
and related their clinical parameters and DAS28 
score to suPAR levels. The median DAS28 score 
(calculated at the time of sampling) was 2.8, cor­
responding to a median low disease activity. All 
the 120 RA patients received a variety of disease
modifying anti-rheumatic drugs (DMARDs); 34 
and 60 RA patients received add-on anti-tumor 
necrosis factor (TNF) therapy and glucocorticoid 
treatment, respectively.
suPAR, CRP and ESR values were higher in RA 
patients compared to healthy individuals (see 
Table). We identified correlation between su­
PAR and DAS28 in RA patients (p=0.02, r=0.26), 
suPAR values and ESR values in RA patients 
(p=0.05, r=0.30) and suPAR values and CRP 
values in healthy individuals (p=0.02, r=0.32). 
CRP and ESR values were also analyzed accord­
ing to DAS28 scores. Irrespectively of anti-TNF 
and glucocorticoid therapy, CRP and ESR values 
were higher with a DAS28 score >2.6 than in RA 
patients in remission (DAS28 score <2.6) or in 
healthy individuals.
The evaluation of RA patients' condition is based 
on laboratory markers and clinical symptoms.
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Appropriate determination of disease activity 
has a significant impact on therapeutic decision 
making process. The elevated suPAR, CRP and 
ESR values are in agreement with earlier results 
indicating higher plasma suPAR levels in RA. 
Furthermore, Slot et al's study indicated a posi­
tive correlation between suPAR and CRP and ESR 
in RA (16). We also found a correlation between 
ESR and DAS28 but not CRP values and suPAR 
levels when all RA patients were analyzed. A 
reason for this apparent controversy might be 
that patients enrolled in our study were more 
heterogeneous in terms of disease severity, in­
cluding patients with milder RA. In contrast with 
the findings in RA, CRP values were correlated 
to suPAR levels in healthy individuals in our 
study either.
When RA patients were grouped according to 
anti-TNF and glucocorticoid therapy, or CRP 
and ESR values, no differences were detected 
between the corresponding therapeutic sub­
groups. However, when we compared RA sub­
groups according to DAS28 scores, a difference 
between remitted RA patients (DAS28 <2.6) and 
patients with different stages of active disease 
(DAS28 >2.6) was detected.
Of note, while CRP and ESR values were com­
parable with healthy individuals in remitted 
patients, suPAR values were still elevated (but 
were lower than in patients with DAS28 >2.6). 
In addition, the number of affected joints was 
strongly correlated to elevated plasma suPAR 
levels, indicating that suPAR levels represent 
well ongoing inflammatory activity in remis­
sion. While CRP and ESR values were similar in 
all subgroups of RA patients in remission to the 
levels seen in healthy individuals, suPAR values 
were elevated indicating the inflammatory ac­
tivity in patients with 2-3 or four affected joints. 
Highest suPAR values were observed in patients 
with the highest number of affected joints. 
This subgroup represented almost 10% of the 
whole RA group of our study and over 20% of
remitted RA patients, indicating that in remitted 
RA regular monitoring of plasma suPAR values 
would support the early detection of inflamma­
tory activity. This is of particular importance as 
recent data indicate that patients in remission 
according to DAS28 scores could have slowly 
progressive structural damage without relevant 
clinical symptoms and with normal CRP and ESR 
(17). In such cases only ultrasound investigation 
of the joints supports the presence of synovitis. 
However, the use of ultrasound has limited as 
its availability is restricted, it is time-consuming, 
and investigator-dependent. Our analysis indi­
cated measuring suPAR with a 4.8 ng/mL cut-off 
value would support the identification of pa­
tients under risk.
These results suggest that suPAR is a sensitive 
marker of inflammatory activity even in remit­
ted RA patients. We identified a subgroup of 
RA patients in remission according to DAS28 
scores, who present still with clinical symptoms 
of inflammatory activity (tender and/or swol­
len joints) which correlate to elevated plasma 
suPAR levels. Importantly, ESR and CRP values 
showed no alteration in these patients com­
pared to healthy controls. Hence, suPAR levels 
might help the follow-up of remitted RA pa­
tients with mild clinical signs. Our finding might 
also have important therapeutic consequenc­
es, since this subgroup identified by elevated 
suPAR levels may benefit from earlier anti-RA 
treatment.
suPAR IN BECHTEREW'S DISEASE (14)
Ankylosing spondylitis (AS) is an immune- 
mediated rheumatic disease characterized by 
chronic inflammation. The autoimmune reac­
tion principally affects the axial and sacroiliac 
joints in AS eventually leading to spondylitis, 
extra bone formation and vertebral fusion (an­
kylosis). In later stages of the disease, systemic 
autoimmune reactions are hallmarked by the
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inflammatory involvement extraskeletal organs 
(eye, gastrointestinal tract or heart). Therefore, 
early and reliable detection and monitoring 
of inflammation and the initiation of targeted 
therapy are of utmost importance in AS.
In order to determine whether suPAR is a mark­
er of inflammation in AS, we enrolled 33 AS pa­
tients. AS patients were classified according to 
the modified New York criteria (18). The median 
of Bath ankylosing spondylitis disease activity in­
dex (BASDAI) was 5.49, indicating an active dis­
ease. Ten of 33 patients received sulfasalazine 
treatment, while 15 of 33 AS patients received 
anti- TNF therapy.
In AS CRP and ESR values were higher than nor­
mal, while suPAR values were comparable to 
the control (see Table). When suPAR levels were 
analyzed according to different subgroups of AS 
patients, AS patients with an ESR value great­
er than 20mm/h exhibited higher suPAR levels 
than those with an ESR value <20mm/h and 
healthy controls. suPAR correlated with CRP 
and ESR values in AS patients. Of note, while 
BASDAI scores correlated with CRP and ESR, 
they did not interact with suPAR.
These observations indicated that suPAR failed 
to detect the ongoing inflammation in AS. This 
pilot study does not support the usefulness of 
suPAR in the assessment of AS.
suPAR AND SYSTEMIC LUPUS 
ERYTHEMATOSUS (12)
Systemic lupus erythematosus (SLE) is a system­
ic autoimmune disease that affects almost all 
vital organs and tissues and is characterized by 
a wide spectrum of clinical signs and symptoms.
Nowadays, C-reactive protein (CRP) is regard­
ed as the gold-standard for the assessment of 
systemic inflammation. However, SLE is an im­
portant exception, as CRP levels are not neces­
sarily elevated and do not reflect inflammation
in SLE (19). In clinical practice, a significantly 
elevated erythrocyte sedimentation rate (ESR) 
with a normal CRP is a strong indicator of SLE. 
ESR is, however, a rather unspecific marker of 
inflammation.
In 89 SLE patients with various stages of dis­
ease duration and activity we aimed to assess 
plasma suPAR levels and to determine if suPAR 
could serve as an inflammatory biomarker in 
SLE. SLE patients were diagnosed and classified 
according to the updated American College of 
Rheumatology (ACR97) criteria (20). The me­
dian of SLE duration was 8 years, and the me­
dian of Systemic Lupus Erythematosus Disease 
Activity Index (SLEDAI) score was 2, correspond­
ing to moderate disease activity (21). Patients 
with a SLEDAI score of 0 were considered to be 
in remission, a SLEDAI score between 1 and 8 
was regarded as moderate disease activity, and 
a SLEDAI score above 8 was regarded as high 
disease activity.
suPAR and ESR values were higher in SLE pa­
tients than in controls, while CRP levels were 
comparable (see Table). We performed further 
analyses of suPAR levels based on several sub­
groups created according to SLE complications. 
Of note, suPAR levels of patients with vasculi­
tis in their history was higher than that of pa­
tients with no vasculitis (5.84 [4.12-7.01] vs. 
4.21 [3.57-5.47] ng/mL, p = 0.04). CRP and ESR 
values did not differ between subgroups of SLE 
patients with different disease activity. suPAR 
levels behaved in a different manner; patients 
with high disease activity exhibited higher su­
PAR levels than those with moderate disease 
activity or in remission.
ROC analysis to discriminate healthy individuals 
and SLE patients based on suPAR yielded an AUC 
of 0.85 (ESR performed in a comparable manner 
with an AUC of 0.87). The cut-off value ofsuPAR 
was 3.54 ng/mL (sensitivity%: 82.02, specifici- 
ty%: 79.31). ROC analysis of suPAR values in SLE
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patients according to SLEDAI scores yielded an 
AUC of 0.68; the cut-off value of suPAR to dis­
criminate between patients with high and with 
moderate disease activity was 5.70 ng/mL (sen- 
sitivity%: 61.54, specificity%: 78.72).
These findings indicate that suPAR levels are el­
evated in SLE. The use of CRP in SLE is limited its 
insensitivity to inflammation in this condition. 
This is due to different factors including de­
creased responsiveness of monocytes produc­
ing CRP-inducing cytokines in SLE, the common 
presence of CRP gene variations associated with 
lower CRP levels and an increased risk of SLE 
and the presence of the autoantibodies against 
CRP in SLE (12)). In contrast with CRP suPAR lev­
els are increased in SLE patients, particularly in 
those with vasculitis. One might hypothesize 
that inflammatory cell adhesion to endothe­
lial cells leading to extravasation into the inti­
ma is promoted by higher suPAR levels in SLE. 
(Indeed, experimental evidence suggests that 
suPAR might promote cell adhesion by binding 
to very late antigen-4 (VLA-4) on inflammatory 
cells as a ligand, promoting their extravasation 
via the activation of other molecules regulating 
cellular adhesion and migration (22)).
Importantly, these results indicate that suPAR 
is a novel marker that may help to discriminate 
between patients with high disease activity 
and those with moderate disease activity or in 
remission.
suPAR IN SYSTEMIC SCLEROSIS (13)
Systemic sclerosis (SSc) is a chronic connective 
tissue disorder characterized by microvascular 
injury, fibrosis and autoimmunity that affects 
the skin and internal organs (23). There are two 
major subtypes of SSc; dcSSc (dominantly af­
fecting the skin) and IcSSc (involving the lung). 
To date, there is still no systemic marker that 
supports the clinical follow-up of organ specific 
disease activity. Currently, erythrocyte ESR and
CRP levels are routinely used to assess SSc dis­
ease activity and severity (24).
We measured suPAR in 83 SSc patients who 
fulfilled the criteria proposed by the American 
College of Rheumatology (25). While CRP levels 
were comparable, suPAR and ESR values were 
higher than normal in SSc patients (see Table). 
suPAR values were higher in IcSSc than in dcSSc 
and correlated with the presence of anti-Scl70. 
Interstitial lung disease assessed by diffus­
ing capacity for carbon monoxide (DLCO) and 
forced vital capacity (FVC) was more severe in 
patients with high suPAR; these parameters cor­
related inversely with suPAR levels. SSc patients 
with pulmonary fibrosis and pulmonary arte­
rial hypertension also exhibited higher suPAR 
levels than those without these complications. 
Microvascular changes including the presence 
of digital ulcers, Raynaud phenomenon and 
NC abnormalities and arthritis were also more 
prevalent with high suPAR values.
These findings support the notion that suPAR 
may provide additional information to tradi­
tional biomarkers that help the objective as­
sessment of complicated SSc.
CONCLUSIONS
These studies indicate that suPAR may be a use­
ful biomarker of inflammation in several types 
of ACTD characterized by low-grade or transient 
inflammatory periods. However, the clinical use 
of suPAR in these conditions requires the clarifi­
cation of several issues.
What suPAR levels should be 
used for decision making?
In several conditions the decision should be 
based on well defined cutoff values; suPAR above 
the limit may indicate an increased risk of inflam­
mation and/or complications. However, based 
on the currently available data it is still uncertain 
which cut-off values are to be used. (The similar
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uncertainty exists for sepsis, a much more exten­
sively investigated condition with different cut­
off values suggested [6,8].)
This uncertainty is partly due to methodological 
issues. It is still unclear whether any change in 
lot numbers / manufacturers would affect the 
results. In addition, the lack of external quality 
control programs for this parameter still pre­
vents the routine use of suPAR.
What is the physiological basis 
ofsuPAR alteration?
suPAR is cleaved from the cell membranes by 
the action of proteases including cathepsin-G, 
PI-PLC, plasmin, Chymotripsin, matrix métallo­
protéases (MMPs) etc. Inflammatory and en­
docrine milieu clearly influences the activity of 
these enzymes, and, probably, suPAR levels. The 
over-activation of the adrenal gland is a com­
mon feature in the diseased patients. Of note, 
adrenal hormones clearly influence MMP activ­
ity and, therefore, may contribute to suPAR pro­
duction (26). Therefore, one may assume that 
any increase of suPAR levels may be a surrogate 
marker of increased adrenal activities. The in­
crease in adrenal hormone levels including glu­
cocorticoids may be due to the progression of 
disease, but is also inherent with therapeutic 
interventions routinely applied in autoimmune 
disorders. However, still there are no data to 
test this possibility.
What clinical factors additional to systemic 
inflammation influence suPAR levels?
The factors and conditions interacting with su­
PAR levels are less clarified. Patients with au­
toimmune disorders often suffer from a poly- 
morbid state and from complications partly 
associated with their background condition. 
Some data indeed demonstrated an inverse as­
sociation between suPAR and renal function and 
a positive association between suPAR and age 
(6). It is unknown, however, how other factors
such as hepatic failure, or different therapeutic 
regimes influence suPAR levels.
From these pilot data suPAR is seemingly a good 
biomarker to obtain an impression whether pa­
tients with SLE, SSc or RA are subjected to an 
increased inflammatory status. However, the 
introduction of such a novel parameter in ev­
eryday practice requires more extensive clini­
cal observations collected during prospective 
studies. The results will serve to decide wheth­
er suPAR is suitable to be used as a clinical bio­
marker in patients with autoimmune connec­
tive tissue disorders.
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